AVOREN: phase III trial of Avastin^© plus IFN

AVOREN: trial design⁸

• The pivotal phase III randomised, double blind, placebo-controlled trial of first-line Avastin^© plus IFN compared with IFN plus placebo in patients with advanced RCC.^8,16
• Trial endpoints
  • primary: OS
  • secondary: PFS, ORR, safety.

• Treatment administration
  • Avastin^© /placebo 10mg/kg every 2 weeks until progression
  • IFN 9MIU three times a week (maximum of 52 weeks; dose reduction allowed).
• Stratification factors: country and MSKCC score.
• Patients were recruited from 101 trial centres in 18 countries (excluding the USA).

AVOREN was a large pivotal, randomised, double-blind, placebo-controlled trial of Avastin^© plus IFN in patients with untreated mRCC